Compugen Ltd. announced today the move and consent of its Intracellular Drug salvation (IDD) ascertainment platform for identification of cell penetrating peptides. Compugen also announced that as part of the concurrence process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating echo in initial exploratory ratification studies.

More: - Continued here